137 related articles for article (PubMed ID: 38868944)
1. The prognostic value of peak oxygen uptake in obstructive hypertrophic cardiomyopathy: a literature review to inform economic model development.
Butzner M; Kinyik-Merena C; Aguiar M; Davison N; Shreay S; Masri A
J Med Econ; 2024; 27(1):817-825. PubMed ID: 38868944
[TBL] [Abstract][Full Text] [Related]
2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Mavacamten in the Treatment of Hypertrophic Cardiomyopathy: A Systematic Review.
Bishev D; Fabara S; Loseke I; Alok A; Al-Ani H; Bazikian Y
Heart Lung Circ; 2023 Sep; 32(9):1049-1056. PubMed ID: 37453852
[TBL] [Abstract][Full Text] [Related]
4. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial.
Olivotto I; Oreziak A; Barriales-Villa R; Abraham TP; Masri A; Garcia-Pavia P; Saberi S; Lakdawala NK; Wheeler MT; Owens A; Kubanek M; Wojakowski W; Jensen MK; Gimeno-Blanes J; Afshar K; Myers J; Hegde SM; Solomon SD; Sehnert AJ; Zhang D; Li W; Bhattacharya M; Edelberg JM; Waldman CB; Lester SJ; Wang A; Ho CY; Jacoby D;
Lancet; 2020 Sep; 396(10253):759-769. PubMed ID: 32871100
[TBL] [Abstract][Full Text] [Related]
5. Study Design and Rationale of EXPLORER-HCM: Evaluation of Mavacamten in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy.
Ho CY; Olivotto I; Jacoby D; Lester SJ; Roe M; Wang A; Waldman CB; Zhang D; Sehnert AJ; Heitner SB
Circ Heart Fail; 2020 Jun; 13(6):e006853. PubMed ID: 32498620
[TBL] [Abstract][Full Text] [Related]
6. Clinical and economic burden of obstructive hypertrophic cardiomyopathy in the United States.
Jain SS; Li SS; Xie J; Sutton MB; Fine JT; Edelberg JM; Gao W; Spertus JA; Cohen DJ
J Med Econ; 2021; 24(1):1115-1123. PubMed ID: 34493144
[TBL] [Abstract][Full Text] [Related]
7. Cardiopulmonary Exercise Testing in Aortic Stenosis.
Le VDT
Dan Med J; 2017 May; 64(5):. PubMed ID: 28552098
[TBL] [Abstract][Full Text] [Related]
8. A systematic review and meta-analysis of the efficacy and safety of Mavacamten therapy in international cohort of 524 patients with hypertrophic cardiomyopathy.
Yacoub MS; El-Nakhal T; Hasabo EA; Shehata N; Wilson K; Ismail KH; Bakr MS; Mohsen M; Mohamed A; Abdelazim E; Ali HT; Soliman Z; Sayed A; Abdelsayed K; Caliskan K; Soliman O
Heart Fail Rev; 2024 Mar; 29(2):479-496. PubMed ID: 38112937
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular outcomes by time-varying New York Heart Association class among patients with obstructive hypertrophic cardiomyopathy: a retrospective cohort study.
Wang Y; Gao W; Han X; Jiang J; Sandler B; Li X; Zema C
J Med Econ; 2023; 26(1):1495-1506. PubMed ID: 37902966
[TBL] [Abstract][Full Text] [Related]
10. Prognostic Value of Peak Oxygen Uptake in Patients Supported With Left Ventricular Assist Devices (PRO-VAD).
Mirza KK; Szymanski MK; Schmidt T; de Jonge N; Brahmbhatt DH; Billia F; Hsu S; MacGowan GA; Jakovljevic DG; Agostoni P; Trombara F; Jorde U; Rochlani Y; Vandersmissen K; Reiss N; Russell SD; Meyns B; Gustafsson F;
JACC Heart Fail; 2021 Oct; 9(10):758-767. PubMed ID: 34391745
[TBL] [Abstract][Full Text] [Related]
11. Cardiopulmonary Exercise Test in Patients with Hypertrophic Cardiomyopathy: A Systematic Review and Meta-Analysis.
Bayonas-Ruiz A; Muñoz-Franco FM; Ferrer V; Pérez-Caballero C; Sabater-Molina M; Tomé-Esteban MT; Bonacasa B
J Clin Med; 2021 May; 10(11):. PubMed ID: 34070695
[TBL] [Abstract][Full Text] [Related]
12. Clinical and prognostic impact of chronotropic incompetence in patients with hypertrophic cardiomyopathy.
Magri D; Agostoni P; Sinagra G; Re F; Correale M; Limongelli G; Zachara E; Mastromarino V; Santolamazza C; Casenghi M; Pacileo G; Valente F; Morosin M; Musumeci B; Pagannone E; Maruotti A; Uguccioni M; Volpe M; Autore C
Int J Cardiol; 2018 Nov; 271():125-131. PubMed ID: 30087038
[TBL] [Abstract][Full Text] [Related]
13. Insights from Cardiopulmonary Exercise Testing in Pediatric Patients with Hypertrophic Cardiomyopathy.
Gallo G; Mastromarino V; Limongelli G; Calcagni G; Maruotti A; Ragni L; Valente F; Musumeci MB; Adorisio R; Rubino M; Autore C; Magrì D
Biomolecules; 2021 Mar; 11(3):. PubMed ID: 33801562
[TBL] [Abstract][Full Text] [Related]
14. [Efficacy of alcohol septal ablation in mildly symptomatic or severely symptomatic patients with hypertrophic obstructive cardiomyopathy].
Sun JJ; Li PJ; Yu XP; Zhao H; Zhang XL; Tu CC; Zhang MD; Jiang TY; Song XT; He JQ
Zhonghua Xin Xue Guan Bing Za Zhi; 2023 May; 51(5):513-520. PubMed ID: 37198123
[No Abstract] [Full Text] [Related]
15. Beyond the black stump: rapid reviews of health research issues affecting regional, rural and remote Australia.
Osborne SR; Alston LV; Bolton KA; Whelan J; Reeve E; Wong Shee A; Browne J; Walker T; Versace VL; Allender S; Nichols M; Backholer K; Goodwin N; Lewis S; Dalton H; Prael G; Curtin M; Brooks R; Verdon S; Crockett J; Hodgins G; Walsh S; Lyle DM; Thompson SC; Browne LJ; Knight S; Pit SW; Jones M; Gillam MH; Leach MJ; Gonzalez-Chica DA; Muyambi K; Eshetie T; Tran K; May E; Lieschke G; Parker V; Smith A; Hayes C; Dunlop AJ; Rajappa H; White R; Oakley P; Holliday S
Med J Aust; 2020 Dec; 213 Suppl 11():S3-S32.e1. PubMed ID: 33314144
[TBL] [Abstract][Full Text] [Related]
16. Study design and rationale of VALOR-HCM: evaluation of mavacamten in adults with symptomatic obstructive hypertrophic cardiomyopathy who are eligible for septal reduction therapy.
Desai MY; Wolski K; Owens A; Naidu SS; Geske JB; Smedira NG; Schaff H; Lampl K; McErlean E; Sewell C; Zhang D; Edelberg JM; Sehnert AJ; Nissen SE
Am Heart J; 2021 Sep; 239():80-89. PubMed ID: 34038706
[TBL] [Abstract][Full Text] [Related]
17. Determinants of peak oxygen uptake in patients with hypertrophic cardiomyopathy: a single-center study.
Magrì D; Agostoni P; Cauti FM; Musumeci B; Egidy Assenza G; De Cecco CN; Muscogiuri G; Maruotti A; Ricotta A; Pagannone E; Marino L; Santini D; Proietti G; Serdoz A; Paneni F; Volpe M; Autore C
Intern Emerg Med; 2014 Apr; 9(3):293-302. PubMed ID: 23054411
[TBL] [Abstract][Full Text] [Related]
18. Combination of Peak Exercise Systolic Blood Pressure and Left Atrial Diameter as a Novel Non-Spirometry Prognostic Predictor Comparable to Peak Oxygen Uptake for Heart Failure With Reduced Ejection Fraction.
Nakanishi M; Miura H; Nakao K; Fujino M; Arakawa T; Fukui S; Hasegawa T; Yanase M; Noguchi T; Goto Y; Yasuda S
Circ J; 2019 Jun; 83(7):1528-1537. PubMed ID: 31142704
[TBL] [Abstract][Full Text] [Related]
19. Exercise Capacity in Patients With Obstructive Hypertrophic Cardiomyopathy: SEQUOIA-HCM Baseline Characteristics and Study Design.
Coats CJ; Maron MS; Abraham TP; Olivotto I; Lee MMY; Arad M; Cardim N; Ma CS; Choudhury L; Düngen HD; Garcia-Pavia P; Hagège AA; Lewis GD; Michels M; Oreziak A; Owens AT; Tfelt-Hansen J; Veselka J; Watkins HC; Heitner SB; Jacoby DL; Kupfer S; Malik FI; Meng L; Wohltman A; Masri A;
JACC Heart Fail; 2024 Jan; 12(1):199-215. PubMed ID: 38032573
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
